4SC integrates Nycomed oncology projects into its portfolio

The German drug discovery and development company, 4SC AG, has restructured its drug portfolio to include oncology projects acquired from Switzerland’s Nycomed in July 2008. It is now preparing to take one of these compounds into Phase 2.